National and Kapodistrian University of Athens
Μελέτη της αιμοσιδήρωσης σε μη-μεταγγιζόμενους ασθενείς με μεσογειακά σύνδρομα: τρόποι θεραπείας και συσχέτιση με κλινικό φαινότυπο και άλλους επιβαρυντικούς παράγοντες
Abstract
dc:descriptionBackground: Patients with thalassemia intermediate (TI) exhibit significant hemosiderosis despite mild clinical presentation and the lack of need for systematic transfusions.Aim: Aim of the study was to record iron levels in a large population with TI, correlate findings with clinical phenotype and other modifying factors and in addition to investigate a satisfactory treatment.Methods: Haemosiderosis levels were evaluated by standard biochemical parameters (serum ferritin, iron, TIBC, transferrin saturation), by newer ones like non-transferrin bound iron (NTBI) and by MRI (LIC, liver Τ2* and heart T2*). Patients were classified according to the distinct criteria used in our clinic, in two clinical phenotypes (I1 heavy and I2 mild) and also according to the number of transfusions to untransfused (including patients with opportunistic transfusions) and patients who had been for a period of time on systematic transfusions. There was no statistically significant difference in the age distribution of the groups in both rankings which allowed for comparisons. Therapeutically in patients with serum ferritin> 450mg/L the new chelator Deferasirox was orally administered, at doses of 10 or 20 mg/kg BW based on serum ferritin value. Treatment success was evaluated after a year’s time based on the reduction of serum ferritin, the reduction of liver iron concentration (LIC) by 3mg Fe/gr of dry tissue and the total LIC level. Results: A total of 70 patients (mean age 23.1 ± 12.5 years) with clinical presentation of TI were studied, 67 (95.7%) with 2 mutations of βthal or δβ genes and 3 heterozygotes of β-thalassemia with co inheritance of a triplicated α gene ( ααα/αα or ααα/ααα). The majority (54.1%) of mutations were β+ (silent, β++ and β+). The most frequent mutation was IVSI-6 (19.1%), followed by IVSI-110 (12.5%), IVSI-1 (9.5%), -101 (8.1%), and CD39 and -87 (with 6.6% each). In many cases the levels of biochemical parameters were found above normal and were also higher in patients with I1 phenotype, like serum ferritin (p<0.001), iron (p<0.001), transferrin saturation (p<0.01) and NTBI (p<0.0001). The iron deposition was not homogeneous since 83.3% of untransfused patients had moderate to severe hepatic haemosiderosis (based on hepatic T2* values) while cardiac T2* values were normal. The value of serum ferritin is not a good marker of total body iron load but strongly correlates with the hepatic load as determined by hepatic T2* (p <0.0002) and LIC (p<0,0001). NTBI was also a good marker as in untransfused patients was independent of age and correlated with serum ferritin (p=0.0047), LIC (p=0.001) and liver T2* (p= 0.0006). Several factors can aggravate the final iron balance. Age correlated with serum ferritin (p=0.0001). Splenectomy increases the liver iron load [correlation with serum ferritin (p<0.0001) and NTBI (p <0.001)]. Patients with a βsil mutation generally have lower serum ferritin and NTBI values than those with β0 and δβ mutations. The presence of HFE mutations in patients aged ≤30 years correlated with increased values of serum ferritin (p=0.025), and TIBC (p=0.002). Treatment of untransfused patients with Deferasirox resulted, after 1 year of treatment, in a significant decrease of serum ferritin (mean decrease 519.5 mg/L, p=0.016) and in all but one patient to a reduction of LIC >3mg Fe/gr of dry tissue (8.9±7.9 mg Fe/gr dry tissue).Conclusions: The study demonstrated the significant haemosiderosis that is progressively presented by a large proportion of Greek TI patients. Iron load correlates with clinical phenotype and is aggravated by various factors such as age, splenectomy and HFE mutations. In monitoring the degree of haemosiderosis of ΤΙ patients, it was demonstrated that serum ferritin is not an accurate marker of total body iron load and should be accompanied by evaluation of other parameters such as LIC, liver T2* and heart T2* with MRI. Treatment with the new oral chelator Deferasirox appears to be safe, facilitates high compliance and gives excellent results in the reduction of iron burden with individually adjusted dosage administration.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Menegas, Damianos
- Μένεγας, Δαμιανός
Subjects
dc:subject × 18- Ενδιάμεση μεσογειακή αναιμία
- Υπερφόρτωση με σίδηρο
- Θεραπεία αποσιδήρωσης
- Δεφερασιρόξη
- Μη-δεσμευμένος με τρανσφερρίνη σίδηρος
- Συγκέντρωση σιδήρου ήπατος
- Κλινικός φαινότυπος
- Thalassemia intermedia
- Iron overload
- Iron chelation therapy
- Deferasirox
- Non-transferrin bound iron (NTBI)
- Liver iron concentration (LIC)
- Clinical phenotype
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/38550